tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Oct;18(10):e13358.
doi: 10.1111/irv.13358. Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation
M Chelsea Lane[SUP] 1 [/SUP], Catherine J Luke[SUP] 1 [/SUP], Joseph Bresee[SUP] 2 [/SUP], Vivien G Dugan[SUP] 3 [/SUP], Diane J Post[SUP] 1 [/SUP], Julie Schafer[SUP] 4 [/SUP], Paul C Roberts[SUP] 1 [/SUP], David E Wentworth[SUP] 3 [/SUP], Michael G Ison[SUP] 1 [/SUP]
Affiliations
On November 13-14, 2023, the National Institute of Allergy and Infectious Diseases (NIAID) in partnership with the Task Force for Global Health, Flu Lab, the Canadian Institutes of Health Research, and the Centers for Disease Control and Prevention convened a meeting on controlled human influenza virus infection model (CHIVIM) studies to review the current research landscape of CHIVIM studies and to generate actionable next steps. Presentations and panel discussions highlighted CHIVIM use cases, regulatory and ethical considerations, innovations, networks and standardization, and the utility of using CHIVIM in vaccine development. This report summarizes the presentations, discussions, key takeaways, and future directions for innovations in CHIVIMs. Experts agreed that CHIVIM studies can be valuable for the study of influenza infection, immune response, and transmission. Furthermore, they may have utility in the development of vaccines and other medical countermeasures; however, the use of CHIVIMs to de-risk clinical development of investigational vaccines should employ a cautious approach. Endpoints in CHIVIM studies should be tailored to the specific use case. CHIVIM studies can provide useful supporting data for vaccine licensure but are not required and do not obviate the need for the conduct of field efficacy trials. Future directions in this field include the continued expansion of capacity to conduct CHIVIM studies, development of a broad panel of challenge viruses and assay reagents and standards that can be shared, streamlining of manufacturing processes, the exploration of targeted delivery of virus to the lower respiratory tract, efforts to more closely replicate natural influenza disease in CHIVIM, alignment on a definition of breadth to facilitate development of more broadly protective/universal vaccine approaches, and continued collaboration between stakeholders.
Keywords: controlled human infection model (CHIM); controlled human infection model (CHIVIM); influenza vaccines; influenza virus.
. 2024 Oct;18(10):e13358.
doi: 10.1111/irv.13358. Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation
M Chelsea Lane[SUP] 1 [/SUP], Catherine J Luke[SUP] 1 [/SUP], Joseph Bresee[SUP] 2 [/SUP], Vivien G Dugan[SUP] 3 [/SUP], Diane J Post[SUP] 1 [/SUP], Julie Schafer[SUP] 4 [/SUP], Paul C Roberts[SUP] 1 [/SUP], David E Wentworth[SUP] 3 [/SUP], Michael G Ison[SUP] 1 [/SUP]
Affiliations
- PMID: 39440405
- PMCID: PMC11496904
- DOI: 10.1111/irv.13358
On November 13-14, 2023, the National Institute of Allergy and Infectious Diseases (NIAID) in partnership with the Task Force for Global Health, Flu Lab, the Canadian Institutes of Health Research, and the Centers for Disease Control and Prevention convened a meeting on controlled human influenza virus infection model (CHIVIM) studies to review the current research landscape of CHIVIM studies and to generate actionable next steps. Presentations and panel discussions highlighted CHIVIM use cases, regulatory and ethical considerations, innovations, networks and standardization, and the utility of using CHIVIM in vaccine development. This report summarizes the presentations, discussions, key takeaways, and future directions for innovations in CHIVIMs. Experts agreed that CHIVIM studies can be valuable for the study of influenza infection, immune response, and transmission. Furthermore, they may have utility in the development of vaccines and other medical countermeasures; however, the use of CHIVIMs to de-risk clinical development of investigational vaccines should employ a cautious approach. Endpoints in CHIVIM studies should be tailored to the specific use case. CHIVIM studies can provide useful supporting data for vaccine licensure but are not required and do not obviate the need for the conduct of field efficacy trials. Future directions in this field include the continued expansion of capacity to conduct CHIVIM studies, development of a broad panel of challenge viruses and assay reagents and standards that can be shared, streamlining of manufacturing processes, the exploration of targeted delivery of virus to the lower respiratory tract, efforts to more closely replicate natural influenza disease in CHIVIM, alignment on a definition of breadth to facilitate development of more broadly protective/universal vaccine approaches, and continued collaboration between stakeholders.
Keywords: controlled human infection model (CHIM); controlled human infection model (CHIVIM); influenza vaccines; influenza virus.